Business Description
BiomX Inc
NAICS : 325412
SIC : 2834
ISIN : US09090D1037
Description
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.99 | |||||
| Equity-to-Asset | 0.12 | |||||
| Debt-to-Equity | 4.9 | |||||
| Debt-to-EBITDA | -0.66 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 28.3 | |||||
| 3-Year EPS without NRI Growth Rate | 26.3 | |||||
| 3-Year FCF Growth Rate | 27.8 | |||||
| 3-Year Book Growth Rate | -70 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 80.18 | |||||
| 9-Day RSI | 65.69 | |||||
| 14-Day RSI | 58.78 | |||||
| 6-1 Month Momentum % | 63.64 | |||||
| 12-1 Month Momentum % | 66.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.58 | |||||
| Quick Ratio | 1.58 | |||||
| Cash Ratio | 1.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -25.5 | |||||
| Shareholder Yield % | -25.35 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -203.54 | |||||
| ROA % | -70.24 | |||||
| ROIC % | -177.17 | |||||
| ROC (Joel Greenblatt) % | -295.14 | |||||
| ROCE % | -89.59 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 5.43 | |||||
| Price-to-Tangible-Book | 5.43 | |||||
| EV-to-EBIT | -0.82 | |||||
| EV-to-Forward-EBIT | -0.58 | |||||
| EV-to-EBITDA | -0.85 | |||||
| EV-to-Forward-EBITDA | -0.58 | |||||
| EV-to-FCF | -0.91 | |||||
| Earnings Yield (Greenblatt) % | -121.95 | |||||
| FCF Yield % | -101.74 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers